Krystal Biotech is trading at $318.01 (6.8% down) today after reporting mixed second-quarter 2026 results where a revenue miss overshadowed an earnings beat.
- Revenue from VYJUVEK reached $119.2M, representing 24% year-over-year growth but falling short of consensus estimates.
- Earnings per share (EPS) of $1.79 exceeded analyst forecasts, driven by improving profitability and solid demand trends.
- The stock is facing pressure as investors scrutinize growth guidance and top-line performance despite the bottom-line beat.